Chinese Endocrinologists Health Education Study

Other illness

• 1\. Subjects with type 1 diabetes, single gene mutation diabetes, diabetes due to pancreatic injury or other secondary diabetes (such as Cushing's syndrome, thyroid dysfunction or acromegaly, etc.);
• 4\. Subjects who were or are using insulin to control diabetes in the past 3 months;
• 5\. History of drug abuse;
• 6\. History of sexually transmitted disease (such as syphilis, and HIV infection \[AIDS\], etc.) or in the active phase of infectious disease (such as viral hepatitis, and tuberculosis, etc.);
• 9\. Any condition that in the judgement of the investigator precludes participation.
  • Details please see the study protocol.

Lab values

• 2\. Subjects with serious cardiovascular diseases, such as congenital heart disease, rheumatic heart disease, hypertrophic or dilated cardiomyopathy and chronic congestive heart failure (NYHA III-IV); acute myocarditis within 12 months; severe liver and kidney dysfunction (eGFR\<60mL/min/1.73m2); mental disorder, etc.

Other

• 3\. Subjects with acute diabetic complications in the past 3 months;
• 7\. Subjects who are pregnant or in lactation;
• 8\. Participation in other clinical trials;

• 1\. Subjects with type 2 diabetes mellitus;
• 2\. First visit to MMC;
• 3\. Age 40-65 years;
• 4\. 24.0 \< BMI ≤ 35.0 kg/m2;
• 5\. Subjects with screening HbA1c ≥ 7.5% and ≤ 10.0%, and the fasting blood glucose ≥ 8.0 mmol/l and \< 13.3 mmol/l;
• 6\. Duration of diabetes less than 10 years;
• 7\. Subjects with poorly controlled blood glucose only by 1-2 kinds of non-insulin hypoglycemic drugs for at least 2 months;
• 8\. Subjects understand the nature, significance, potential benefits, inconvenience, and risks of the study before it starts, and fully understand the study procedures and voluntarily sign the informed consent form.